Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Fluorouracil 51Oxaliplatin 49Gemcitabine 47Leucovorin 41Capecitabine 35Bevacizumab 29Irinotecan 25Cisplatin 22Radiotherapy 18Radiosurgery 18pembrolizumab 16Nivolumab 16Cetuximab 15Taxes 14Sorafenib 14Paclitaxel 13Biopsy 13Surgical Procedures, Operative 12Drug Therapy 11atezolizumab 10Radiation 10Albumin-Bound Paclitaxel 10lenvatinib 9durvalumab 9Magnetic Resonance Spectroscopy 9Folfox protocol 9Cyclophosphamide 9130-nm albumin-bound paclitaxel 9spartalizumab 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Vancomycin × Gastrointestinal × Clear all
NCT04025567 2020-03-16

Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡